)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
StageZero Life Sciences
StageZero Life Sciences (SZLS) investor relations material
StageZero Life Sciences has been otc
StageZero Life Sciences Q3 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2024 earnings summary15 Dec, 2024
Executive summary
Q3 2024 focused on revitalizing corporate offerings and integrating operational changes from Q2 and Q3 to drive uptake of the Aristotle test and increase revenues.
Strategic review led to cost reductions, improved competitiveness, and operational realignment, including lab relocation and expanded clinical support in Europe and North America.
Financial highlights
Q3 2024 revenue was $0.5M, down from $0.745M in Q3 2023; net loss narrowed to $0.399M from $0.822M year-over-year.
Nine-month 2024 revenue was $1.412M, compared to $2.206M in the same period of 2023; net loss reduced to $1.435M from $3.035M year-over-year.
Operating costs decreased by approximately 50% due to operational changes.
Outlook and guidance
Revenue is expected to ramp up over the next twelve months as Aristotle testing scales and new partnerships are launched.
Company anticipates paying auditors by December 31, 2024, and is seeking a partial revocation of the FFCTO to enable potential equity or debt funding.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from StageZero Life Sciences
StageZero Life Sciences
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
StageZero Life Sciences Ltd. specializes in providing molecular diagnostic solutions, leveraging a telehealth program that employs advanced diagnostics for the early detection of cancer and chronic diseases. The company is known for developing blood-based biomarker tests, particularly for identifying colorectal cancer. A key innovation from StageZero is its Sentinel Principle technology, which is instrumental in early disease diagnosis, staging, response identification, and treatment monitoring. Additionally, StageZero offers Aristotle, an mRNA-based test capable of detecting multiple cancers from a single blood sample. StageZero Life Sciences is headquartered in Richmond Hill, Ontario, and its shares are listed on the Toronto Stock Exchange.